These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21871426)

  • 1. p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.
    Proust A; Rincé P; Creidy R; Lazure T; Joab I; Garçon L; Fabre M; Guettier C; Raphael M
    Am J Pathol; 2011 Oct; 179(4):1630-7. PubMed ID: 21871426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 expression and survival in posttransplant lymphoproliferative disorders.
    Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
    Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
    [No Abstract]   [Full Text] [Related]  

  • 3. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
    Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Noujima-Harada M; Takata K; Miyata-Takata T; Sakurai H; Igarashi K; Ito E; Nagakita K; Taniguchi K; Ohnishi N; Omote S; Tabata T; Sato Y; Yoshino T
    Cancer Sci; 2017 May; 108(5):1071-1079. PubMed ID: 28256087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
    Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
    Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
    Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
    Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.
    Menter T; Dickenmann M; Juskevicius D; Steiger J; Dirnhofer S; Tzankov A
    Hematol Oncol; 2017 Jun; 35(2):187-197. PubMed ID: 26799990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders.
    Morscio J; Dierickx D; Ferreiro JF; Herreman A; Van Loo P; Bittoun E; Verhoef G; Matthys P; Cools J; Wlodarska I; De Wolf-Peeters C; Sagaert X; Tousseyn T
    Am J Transplant; 2013 May; 13(5):1305-16. PubMed ID: 23489474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.
    Huang YC; Lin SJ; Lin KM; Chou YC; Lin CW; Yu SC; Chen CL; Shen TL; Chen CK; Lu J; Chen MR; Tsai CH
    Blood; 2016 Sep; 128(12):1578-89. PubMed ID: 27338098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
    Salmerón-Villalobos J; Castrejón-de-Anta N; Guerra-García P; Ramis-Zaldivar JE; López-Guerra M; Mato S; Colomer D; Diaz-Crespo F; Menarguez J; Garrido-Pontnou M; Andrés M; García-Fernández E; Llavador M; Frigola G; García N; González-Farré B; Martín-Guerrero I; Garrido-Colino C; Astigarraga I; Fernández A; Verdú-Amorós J; González-Muñíz S; González B; Celis V; Campo E; Balagué O; Salaverria I
    Blood; 2023 Aug; 142(5):434-445. PubMed ID: 37053555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
    Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
    J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).
    Kuo SH; Tsai HJ; Lin CW; Yeh KH; Lee HW; Wei MF; Shun CT; Wu MS; Hsu PN; Chen LT; Cheng AL
    J Pathol; 2017 Feb; 241(3):420-433. PubMed ID: 27873317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Kabasawa N; Shiozawa E; Murai S; Homma M; Uesugi Y; Matsui T; Nakata A; Shimada S; Sasaki Y; Baba Y; Watanuki M; Arai N; Fujiwara S; Kawaguchi Y; Tsukamoto H; Uto Y; Yanagisawa K; Hattori N; Sakai H; Harada H; Nakamaki T; Takimoto M; Yamochi-Onizuka T
    J Clin Exp Hematop; 2021; 61(3):120-125. PubMed ID: 34511544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells.
    Shen X; Zhu W; Zhang X; Xu G; Ju S
    Mol Cell Biochem; 2011 Nov; 357(1-2):21-30. PubMed ID: 21607696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.